Sign In
Buy FATE
$2.22
-0.350 (-13.62%)
At Close: Jun 03, 2026
Fate Therapeutics: iPSC Pioneer A Buy For Long-Term Investors
06:00am, Thursday, 05'th Jan 2023
Shares have fallen by over 80% during the past 12 months. iPSC-derived NK cell programs sport advantages such as streamlined manufacturing, optimization and convenient administration.
Fate Therapeutics (FATE) Loses -50.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:17am, Tuesday, 03'rd Jan 2023
Fate Therapeutics (FATE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings e
Fate Therapeutics: Returning To The Ticker That Changed The Way I Invest
01:47am, Tuesday, 15'th Nov 2022
Fate Therapeutics was one of my favorite investments, however, I made the haunting mistake of closing the position only to see the ticker nearly triple. This time will be different. FATE has lost roug
Fate Therapeutics to Present at Upcoming Investor Conferences
04:01pm, Friday, 04'th Nov 2022
SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm
Fate Therapeutics, Inc. (FATE) Q3 2022 Earnings Call Transcript
11:56pm, Thursday, 03'rd Nov 2022
Fate Therapeutics, Inc. (NASDAQ:FATE ) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Ed Dulac - Chief Financial
Fate Therapeutics to Participate at Upcoming September Investor Conferences
08:00am, Friday, 02'nd Sep 2022
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develop
The 5 Top Stocks Cathie Wood Is Buying Now
02:56pm, Monday, 15'th Aug 2022
Cathie Wood's Ark Invest has performed well recently, with shares of her flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEMKT: ARKK ), up more than 15% during the past month. The perfo
3 Cathie Wood Stocks for the Future
11:13am, Sunday, 14'th Aug 2022
Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.
Cathie Wood Is Buying Up Red-Hot Fate Therapeutics (FATE) Stock
04:07pm, Friday, 12'th Aug 2022
Source: ra2 studio/Shutterstock Shares of Fate Therapeutics (NASDAQ: FATE ) stock are up 3% following a massive purchase by two of Cathie Wood's exchange-traded funds (ETFs). Fate is a clinical stage
ARK's Cathie Wood Dumps More Twitter Stock, Buys $20M in Fate Therapeutics Stock
09:29am, Friday, 12'th Aug 2022
Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm's exchange-traded funds (E
7 Small-Cap Stocks to Buy Before the Bull Market Returns
02:15pm, Sunday, 07'th Aug 2022
Small-cap stocks with lower market capitalizations ranging from $300 million to $2 billion have taken quite a hit since January. These stocks typically belong to smaller companies with massive long-te
FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus
12:47pm, Thursday, 04'th Aug 2022
FATE reports a narrower loss and higher collaboration revenues in the second quarter.
Fate Therapeutics Inc. (FATE) CEO Scott Wolchko on Q2 2022 Results - Earnings Call Transcript
10:55am, Thursday, 04'th Aug 2022
Fate Therapeutics Inc. (NASDAQ:FATE ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Yu-Waye Chu - Chief Medical Offic
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 03'rd Aug 2022
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 8.14% and 38.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
04:01pm, Monday, 25'th Jul 2022
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develop
